<DOC>
	<DOCNO>NCT01470131</DOCNO>
	<brief_summary>The purpose study compare efficacy safety masitinib 6 mg/kg/day combination bortezomib dexamethasone placebo combination bortezomib dexamethasone treatment patient relapse multiple myeloma receive one previous therapy .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Efficacy Safety Masitinib Patients With Relapse Refractory Multiple Myeloma</brief_title>
	<detailed_description>This prospective , multicenter , randomize , double-blind , placebo-controlled , 2-parallel group , phase 3 study compare efficacy safety masitinib 9 mg/kg/day placebo treatment patient relapse multiple myeloma receive one previous therapy . Patients receive study treatment ( masitinib/placebo ) standard therapy ( bortezomib dexamethazone ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patient confirm multiple myeloma require systemic therapy . All three criterion must meet : Clonal bone marrow plasma cell &gt; 10 % Presence serum and/or urinary monoclonal protein Evidence endorgan damage attribute underlying plasma cell proliferative disorder , specifically : Hypercalcemia : serum calcium &gt; 11.5 mg/100 ml Renal insufficiency : serum creatinine &gt; 173 µmol/l Anemia : normochromic , normocytic hemoglobin value &gt; 2g/100 ml low limit normal hemoglobin value &lt; 10g/100 ml Bone lesion : lytic lesion , severe osteopenia pathologic fracture 2 . Patient multiple myeloma relapse accord International uniform response criterion multiple myeloma ( IMWG 2009/ revise Bladé criterion ) one previous line treatment 3 . Patient measurable progressive disease define least one follow two measurement : Serum Mprotein ≥ 1 g/dL Urine Mprotein ≥ 200 mg/24h 1 . Patient peripheral neuropathy Grade &gt; 2 2 . Patient hypersensitivity bortezomib , boron dexamethasone 3 . Patient whose disease progress within 60 day bortezomib treatment Multiple Myeloma therapy 4 . Patient receive bortezomib within 6 month randomization study 5 . Past discontinuation bortezomib due associate grade 3 high adverse event 6 . Patient contraindication high dose steroid ( include ongoing active infection , use live vaccine , virosis hepatitis , herpes , varicella , herpes zoster )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>relapse</keyword>
	<keyword>second line therapy</keyword>
	<keyword>bortezomib</keyword>
	<keyword>dexamethasone</keyword>
</DOC>